Skip to main content English

Klinische Studien

Gastroesophageal Tumor Unit (CCC-GET)


  • pANCHO p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer (NCT00525200)
  • MIOMIE prospective randomized trial for the evaluation of perioperative morbidity in patients with esophageal cancer - open versus minimally invasive esophagectomy
  • GABIS Gastroesophageal Cancer Biopsy Studie - Evaluation of Tumorheterogenity of Her-2 expression in patients with gastroesophageal cancer
  • SAS-1 Study - Evaluation for Radiofrequency ablation in combination with anti-reflux procedure in patients with low-grade dysplasia and non-dysplastic Barretts
  • Phase II study of Oxaliplatin/ Irinotecan/ Bevacizumab followed by Docetaxel/ Bevacizumab in inoperable locally advanced or metastatic gastric cancer patients


  • Indikationserweiterungsstudie bei Patient:innen mit minimal metastasierten gastroösophagealen Karzinomen
  • SAKK  75/08.  Multimodal  therapy  with  and  without  cetuximab  in  patients  with  locally  advanced esophageal carcinoma. An open-label phase III trial
  • Screening for human epidermal growth factor receptor 2 (HER2) positivity in patients with inoperable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer
  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in c-Met Enriched Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
  • Phase II trial of the long-acting somatostatin analogue octreotide (Sandostatin LAR) combined with chemotherapy consisting of 5-FU/Cisplatin in patients with advanced gastric cancer